Sulfasalazine
Azulfidine (sulfasalazine) is a small molecule pharmaceutical. Sulfasalazine was first approved as Azulfidine on 1982-01-01. It is used to treat juvenile arthritis, rheumatoid arthritis, and ulcerative colitis in the USA. It is known to target proton-coupled folate transporter.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Azulfidine, Azulfidine en-tabs (generic drugs available since 1982-01-01, discontinued: S.a.s)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| azulfidine | New Drug Application | 2021-03-12 |
| sulfasalazine | ANDA | 2023-06-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| juvenile arthritis | EFO_0002609 | D001171 | M08 |
| rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
| ulcerative colitis | EFO_0000729 | D003093 | K51 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
58 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 9 | 13 | 3 | 25 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 2 | 1 | 3 | — | 5 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | 1 | 2 | — | 3 |
| Spondylarthritis | D025241 | — | — | — | 1 | — | 1 | ||
| Heart disease risk factors | D000082742 | — | — | — | 1 | — | 1 | ||
| Vascular stiffness | D059289 | — | — | — | 1 | — | 1 | ||
| Juvenile arthritis | D001171 | EFO_0002609 | M08 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | — | — | 1 | — | — | 1 | |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | 2 | 1 | — | — | — | 2 | |
| Pulmonary arterial hypertension | D000081029 | 1 | 1 | — | — | — | 1 | ||
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 1 | — | — | — | 1 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | 1 | |
| Sclerosing cholangitis | D015209 | EFO_0004268 | K83.01 | — | 1 | — | — | — | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 1 | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | — | 3 | ||
| Intestinal obstruction | D007415 | K56.60 | 2 | — | — | — | — | 2 | |
| Magnetic resonance imaging | D008279 | 1 | — | — | — | — | 1 | ||
| Oral administration | D000284 | 1 | — | — | — | — | 1 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Vomiting | D014839 | HP_0002013 | R11.1 | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
| Glioma | D005910 | EFO_0000520 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal neoplasms | D004938 | C15 | — | — | — | — | 1 | 1 | |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | 1 | 1 | |
| Dumping syndrome | D004377 | EFO_1001307 | K91.1 | — | — | — | — | 1 | 1 |
| Feeding and eating disorders | D001068 | F50 | — | — | — | — | 1 | 1 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | — | 1 | 1 |
| Coronary artery disease | D003324 | I25.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SULFASALAZINE |
| INN | sulfasalazine |
| Description | Sulfasalazine, sold under the brand name Azulfidine among others, is a medication used to treat rheumatoid arthritis, ulcerative colitis, and Crohn's disease. It is considered by some to be a first-line treatment in rheumatoid arthritis. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | antiarrhythmic/antianginal/antihypertensive agents, phthalazine like structure; anti-inflammatory agents (salicylic acid derivatives); antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O |
Identifiers
| PDB | — |
| CAS-ID | 599-79-1 |
| RxCUI | 9524 |
| ChEMBL ID | CHEMBL421 |
| ChEBI ID | 9334 |
| PubChem CID | 5353980 |
| DrugBank | DB00795 |
| UNII ID | 3XC8GUZ6CB (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC46A1
SLC46A1
Organism
Homo sapiens
Gene name
SLC46A1
Gene synonyms
G21, HCP1, PCFT
NCBI Gene ID
Protein name
proton-coupled folate transporter
Protein synonyms
Heme carrier protein 1, PCFT/HCP1, solute carrier family 46 (folate transporter), member 1, Solute carrier family 46 member 1
Uniprot ID
Mouse ortholog
Slc46a1 (52466)
proton-coupled folate transporter (Q9D1P1)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,374 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
34 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more